Venus Remedies gets Mexico patent for Potentox

CHANDIGARH: Venus Remedies has received patent from Mexico for its novel antibiotic Potentox. Granted by the Mexican Institute of Industrial Property (IMPI), the patent protects the composition of Potentox, the company said here on Monday.

It said the patent provides an exclusivity period for Potentox up to 2025. The drug is also protected by patents from various other countries, including USA, India, Australia, New Zealand, South Korea, South Africa, Canada and Ukraine, it said.

Potentox is an antibiotic adjuvant entity (AAE), a drug effective to treat cases of hospital-acquired pneumonia and febrile neutropenia infections, primarily caused by quinolones or aminoglycoside-resistant microbes, it said.

On the response to the product, the release quoting Dheeraj Aggarwal, CEO, Venus Remedies Ltd, said, "the product is growing at a compound annual growth rate of 50% since the past three years. "To take this novel antibiotic adjuvant entity to Mexico, the company is already holding talks with some big pharmaceutical companies there for strategic tie-ups. "We will soon be filing it. But it will take us another two-three years to launch the product in this market."